Rigel Pharmaceuticals, Inc.

Investors News & Events Contact Us
  • Home
  • Who We Are
    • Company Overview
    • Management Team
    • Board of Directors
    • Partners
  • Pipeline
    • Clinical Programs
    • IRAK1/4
    • RIPK1
    • Partnered Programs
    • Clinical Trials
    • Investigator Sponsored Research
    • Expanded Access Policy
  • Products
  • Join Our Team
    • Life at Rigel
    • Our Values
    • Benefits
    • Current Openings
  • Investors
  • News & Events
  • Contact Us

Press Releases

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events
Jul 23, 2009 12:00pm EDT

Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi3 Clinical Trial of R788 in Rheumatoid Arthritis

Jul 09, 2009 6:00am EDT

Rigel's R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial

Jul 08, 2009 9:00pm EDT

Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis

Jun 10, 2009 7:30am EDT

Rigel to Present at Jefferies Healthcare Conference

Jun 01, 2009 7:30am EDT

Rigel's R788 Evaluated in Phase 2 Trial in Multiple Cancers

May 13, 2009 7:30am EDT

Rigel to Present at JMP Securities Research Conference

May 05, 2009 7:00am EDT

Rigel Announces First Quarter 2009 Financial Results

Feb 24, 2009 6:00am EST

Rigel Announces Fourth Quarter and Year End 2008 Financial Results

Feb 05, 2009 7:30am EST

Rigel to Present at BIO CEO & Investor Conference

Feb 03, 2009 6:00am EST

Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results

  • Previous
  • 1…
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • …42
  • Next
RSS
Terms of Use Privacy Policy Your Cookie Preferences

© 2025 Rigel Pharmaceuticals, Inc. All Rights Reserved.

TAVALISSE, TAVLESSE, REZLIDHIA, GAVRETO, RIGEL and the Rigel arc logo are registered trademarks of Rigel Pharmaceuticals, Inc.

Facebook X Linkedin